Cited 5 times in
Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 신동호 | - |
dc.contributor.author | 홍명기 | - |
dc.date.accessioned | 2014-12-19T16:50:05Z | - |
dc.date.available | 2014-12-19T16:50:05Z | - |
dc.date.issued | 2012 | - |
dc.identifier.issn | 1477-9072 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/90283 | - |
dc.description.abstract | Percutaneous coronary intervention is evolving rapidly. Among the developments in various aspects, dual antiplatelet therapy (DAPT) has played a pivotal role to reduce thrombotic events after stent implantation. After the introduction of the drug-eluting stent, prolonged DAPT has been recommended due to concerns regarding late and very late stent thrombosis. However, there are controversies regarding the benefit of long-term DAPT. In addition, prolonged DAPT accompanies increased bleeding risk as well as additional cost. To balance the benefit and risk, optimizing DAPT duration is crucial. In this article, clinical guidelines and studies regarding optimal duration of DAPT are discussed. | - |
dc.description.statementOfResponsibility | open | - |
dc.relation.isPartOf | EXPERT REVIEW OF CARDIOVASCULAR THERAPY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Drug-Eluting Stents* | - |
dc.subject.MESH | Hemorrhage/chemically induced | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Percutaneous Coronary Intervention/methods* | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/administration & dosage | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/adverse effects | - |
dc.subject.MESH | Platelet Aggregation Inhibitors/therapeutic use* | - |
dc.subject.MESH | Practice Guidelines as Topic | - |
dc.subject.MESH | Thrombosis/prevention & control | - |
dc.subject.MESH | Time Factors | - |
dc.title | Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Dong-Ho Shin | - |
dc.contributor.googleauthor | Myeong-Ki Hong | - |
dc.identifier.doi | 10.1586/erc.12.113 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A02097 | - |
dc.contributor.localId | A04391 | - |
dc.relation.journalcode | J00879 | - |
dc.identifier.eissn | 1744-8344 | - |
dc.identifier.pmid | 23190066 | - |
dc.identifier.url | http://www.expert-reviews.com/doi/abs/10.1586/erc.12.113 | - |
dc.subject.keyword | drug-eluting stent | - |
dc.subject.keyword | dual antiplatelet therapy | - |
dc.subject.keyword | percutaneous coronary intervention | - |
dc.subject.keyword | thienopyridine | - |
dc.contributor.alternativeName | Shin, Dong Ho | - |
dc.contributor.alternativeName | Hong, Myeong Ki | - |
dc.contributor.affiliatedAuthor | Shin, Dong Ho | - |
dc.contributor.affiliatedAuthor | Hong, Myeong Ki | - |
dc.citation.volume | 10 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1273 | - |
dc.citation.endPage | 1285 | - |
dc.identifier.bibliographicCitation | EXPERT REVIEW OF CARDIOVASCULAR THERAPY, Vol.10(10) : 1273-1285, 2012 | - |
dc.identifier.rimsid | 34115 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.